

Clinical Trial Protocol

Iranian Registry of Clinical Trials

16 Sep 2026

Evaluating the effect of ursodeoxycholic acid in reducing hospitalization for intensive phototherapy in neonates with indirect hyperbilirubinemia referred to outpatient clinics in comparison with the control group

Protocol summary

Study aim

Investigate the effect of Ursodioxycholic acid (UDCA) in reducing hospital admission rate for intensive phototherapy in neonate with indirect hyperbilirubinemia

Design

This is a clinical trial study phase 3 in neonates with hyperbilirubinemia which performs in two parallel groups receiving drug and placebo. The study is a triple blind, block randomized design. The sample size is calculated to be 148.

Settings and conduct

The study is performed on neonate with jaundice who are brought to Imam Reza , Hazrat Zeinab or Hafez outpatient clinics in Shiraz. Caregivers, physicians, and data analysts are not aware of the type of treatment.

Participants/Inclusion and exclusion criteria

Neonates with a bilirubin between 3 mg / dL less than required for intensive phototherapy and the level required for intensive phototherapy in hospital participate in this study. All of these neonates need phototherapy at home. Other inclusion criteria: neonate with gestational age 35 weeks or more, exclusive breastfeeding, age over one day and direct bilirubin below 2 mg / dL . Exclusion criteria: Blood incompatibility, cardiac or liver disease , infection and sepsis or infant of diabetic mother

Intervention groups

Ursodioxycholic acid suspension (prepared from 300 mg capsule of Alborz Darou Pharmaceutical Co. as a suspension of 60 mg / 1cc) prescribe orally as 10 mg /kg body weight of the neonate, divided into 2 doses every 12 hours . At the same intervals, the control group is given the same volume of placebo. Both groups receive medication or placebo until their bilirubin drops below 3 units less than intensive phototherapy level.

Main outcome variables

Hospitalization rate for intensive phototherapy; Total

bilirubin; Medication side effects (nausea, vomiting, skin rash)

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20190604043813N4**

Registration date: **2021-06-21, 1400/03/31**

Registration timing: **prospective**

Last update: **2021-06-21, 1400/03/31**

Update count: **0**

Registration date

2021-06-21, 1400/03/31

Registrant information

Name

Hourvash Akbari Haghighinejad

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 71 3647 4967

Email address

hhaghighi@sums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-08-23, 1400/06/01

Expected recruitment end date

2022-08-23, 1401/06/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date
empty

Scientific title
Evaluating the effect of ursodeoxycholic acid in reducing hospitalization for intensive phototherapy in neonates with indirect hyperbilirubinemia referred to outpatient clinics in comparison with the control group

Public title
Effect of ursodeoxycholic acid in reducing hospitalization for phototherapy

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
Exclusive breastfeeding, Age above 1 day Neonate born with gestational age 35 weeks or more Total bilirubin between 3 mg / dL less than the level required for intensive phototherapy treatment in the hospital and the level required for hospitalization Direct bilirubin levels below 2 mg / dL. Parent consent Infants whose parents agree not to use herbal or traditional medicines during the study period.
Exclusion criteria:
Rh incompatibility Underlying disease such as heart and liver disease Infection and septicemia Neonate of diabetic mother

Age
From **2 days** old to **15 days** old

Gender
Both

Phase
3

Groups that have been masked

- Participant
- Care provider
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

Sample size
Target sample size: **148**
More than 1 sample in each individual
Number of samples in each individual: **3**
Total bilirubin

Randomization (investigator's opinion)
Randomized

Randomization description
The block randomization list with block size of 4 generates by
<https://www.sealedenvelope.com/simple-randomiser/v1/lits>. The sample size , size of blocks and study groups are given to the system, and the system determines the order of the blocks and the order in each block in a list.
The drug and placebo are arranged in a box according to the list by a pharmacist and are given to a doctor who is responsible for the research to be given to the neonates.

Blinding (investigator's opinion)
Triple blinded

Blinding description

The drug and placebo which are prepared in syrup and are distinguishable by A and B labels will be arranged in a box according to the randomization list by the pharmacist who has no responsibility for patients care . The box will be given to a doctor who is unaware of the intervention type and he give the treatment in specified order . Caregivers, physicians are not aware of the treatment. The results are compiled and analyzed by a statistician who is not aware of the intervention type.

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of research of Shiraz Medical School
Street address
Family medicine department , Namazi Hospital, Zand street
City
Shiraz
Province
Fars
Postal code
7184983858
Approval date
2021-05-03, 1400/02/13
Ethics committee reference number
IR.SUMS.MED.REC.1400.076

Health conditions studied

1

Description of health condition studied
Neonatal indirect hyperbilirubinemia
ICD-10 code
P59
ICD-10 code description
Neonatal jaundice from other and unspecified causes

Primary outcomes

1

Description
Hospitalization rate
Timepoint
Weekly, from week 1 to 4 after the start of the intervention
Method of measurement
Asking the parents about admission in hospital for

phototherapy

Secondary outcomes

1

Description

Total bilirubin

Timepoint

Every 24 hours until the bilirubin reaches 3 mg / dl below the level required for intensive phototherapy

Method of measurement

Capillary method and diazo laboratory method

2

Description

Adverse effect of drug

Timepoint

Till 4 weeks after the start of the drug

Method of measurement

Asking the parents about adverse effect

Intervention groups

1

Description

Intervention group: The intervention group will receive oral drug of Ursodeoxycholic acid (UDCA) 10 mg/kg (1/6cc/kg) daily divided into 2 doses every 12 hours. UDCA 300 mg capsule (provided by Alborz Darou Company, Tehran, Iran) is used for the preparation of 60 mg/1cc suspension. Both intervention and control groups receive standard phototherapy at home and the baby's eye and genitalia are covered. The drug is continued until the bilirubin level is below 3mg /dl lower than the level require for intensive phototherapy.

Category

Treatment - Drugs

2

Description

Control group: At 12 hours intervals, the control group received the same volume placebo suspension (1/6cc/kg). Both intervention and control groups receive standard phototherapy at home and the baby's eye and genitalia are covered. The drug is continued until the bilirubin level is below 3mg /dl lower than the level require for intensive phototherapy.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Imam Reza clinic

Full name of responsible person

Mehrdad Rezaie

Street address

Zand street. Nemazi Square.

City

Shiraz

Province

Fars

Postal code

7184983858

Phone

+98 71 3647 4967

Fax

+98 71 3647 4967

Email

hhaghighi@sums.ac.ir

2

Recruitment center

Name of recruitment center

Clinic of Hafez hospital

Full name of responsible person

Mehrdad Rezaie

Street address

Abiverdi Blvd.

City

Shiraz

Province

Fars

Postal code

7184983858

Phone

+98 71 3647 4967

Fax

+98 71 3647 4967

Email

md_rezaie@yahoo.co.uk

3

Recruitment center

Name of recruitment center

Clinic of Zeinabiye Hospital

Full name of responsible person

Mehrdad Rezaie

Street address

Sibuye Blvd.

City

Shiraz

Province

Fars

Postal code

7184983858

Phone

+98 71 3647 4967

Fax

+98 71 3647 4967

Email

md_rezaie@yahoo.co.uk

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Abbas Rezaianzadeh

Street address

Zand Street

City

Shiraz

Province

Fars

Postal code

7194983858

Phone

+98 71 3647 4967

Fax

+98 71 3647 4967

Email

vcrdep@sums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shiraz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Hourvash Akbari Haghighinejad

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Family Physician

Street address

Family Medicine Department, Namazi Hospital, Zand Street,

City

Shiraz

Province

Fars

Postal code

7194983858

Phone

+98 71 3647 4967

Fax

+98 71 3647 4967

Email

hhaghighi@sums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Hourvash Akbari Haghighinejad

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Family Physician

Street address

Family Medicine Department, Namazi Hospital, Zand Street,

City

Shiraz

Province

Fars

Postal code

7194983858

Phone

+98 71 3647 4967

Fax

+98 71 3647 4967

Email

hhaghighi@sums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Hourvash Akbari Haghighinejad

Position

Assistant professor

Latest degree

Specialist

Other areas of specialty/work

Family Physician

Street address

Zand street, Namazi hospital, Family medicine department

City

Shiraz

Province

Fars

Postal code

7184983858

Phone

+98 71 3647 4967

Fax

+98 71 3647 4967

Email

hhaghighi@sums.ac.ir

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Not applicable

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

After the publication of the main article, all collected de-identified IPD can be shared.

When the data will become available and for how long

From the time of publication until 6 months later

To whom data/document is available

All people who request to access the documents

Under which criteria data/document could be used

After the publication of the main article, if the source of the main study is mentioned, the data will be available for systematic review and meta-analysis.

From where data/document is obtainable

hhaghighi@sums.ac.ir

What processes are involved for a request to access data/document

The request can be sent to the email adress mentioned above

Comments